BRAF and endocrine system disorder: AVP-D was noted in a significant proportion of patients with ECD accompanied by a large burden of other endocrinopathies, more hypotonic urine despite vasopressin therapy, the absence of posterior pituitary bright spots, and pathogenic variants in BRAF V600E compared to those without AVP-D.